Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641334 | 1.00 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL10729971 | 1.00 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL2948325 | 0.82 | NPSR1 (0.56) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL9512735 | 0.82 | NPSR1 (0.56) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL2952591 | 0.82 | NPSR1 (0.56) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL18290046 | 0.80 | NPSR1 (0.54) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL11445029 | 0.80 | NPSR1 (0.54) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL15482738 | 0.79 | NPSR1 (0.48) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL15482740 | 0.78 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL18536698 | 0.78 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224189-B1 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
| US-6686376-B2 | INHIBITING A RESISTANT NEOPLASM, OR A NEOPLASM SUSCEPTIBLE TO RESISTANCE IN A MAMMAL WHICH COMPRISES ADMINISTERING COMPOUND OF INVENTION | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6670373-B1 | Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide | ELI LILLY AND COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030232854-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1296953-A2 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1224189-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002000624-A2 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001027116-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232854-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ABCC1, ABCB11, ABCB1 | NPSR1 1483/4885HCAR2 2813/4885ALDH1A1 211/4885 |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | NPSR1 1359/4885HCAR2 2941/4885ALDH1A1 208/4885 |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | ABCC1, ABCB1, ABCB11 | NPSR1 3966/4885HCAR2 4030/4885ALDH1A1 212/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | NPSR1 1536/4885HCAR2 2711/4885ALDH1A1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.